- Home
- BNKK vs CRIS Comparison
BNKK vs CRIS Comparison
Compare BNKK & CRIS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BNKK | CRIS |
|---|---|---|
| Founded | 2018 | 2000 |
| Country | United States | United States |
| Employees | 8 | N/A |
| Industry | Package Goods/Cosmetics | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.3M | 14.0M |
| IPO Year | N/A | 2000 |
Fundamental Metrics
Financial Performance| Metric | BNKK | CRIS |
|---|---|---|
| Price | $1.64 | $0.52 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $17.00 |
| AVG Volume (30 Days) | ★ 320.6K | 223.9K |
| Earning Date | 05-14-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 91.57 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $9,898,000.00 |
| Revenue This Year | N/A | $27.10 |
| Revenue Next Year | N/A | $67.74 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 31.50 |
| 52 Week Low | $0.11 | $0.46 |
| 52 Week High | $7.19 | $3.13 |
Technical Indicators
Market Signals| Indicator | BNKK | CRIS |
|---|---|---|
| Relative Strength Index (RSI) | 26.73 | 43.39 |
| Support Level | $0.12 | $0.48 |
| Resistance Level | $2.90 | $0.63 |
| Average True Range (ATR) | 0.25 | 0.04 |
| MACD | -0.06 | 0.00 |
| Stochastic Oscillator | 0.00 | 34.62 |
Price Performance
Historical ComparisonAbout BNKK Bonk Inc.
Bonk Inc is a publicly traded company focused on building a digital asset treasury centered around the BONK ecosystem on the Solana blockchain. It generates revenue through a recurring interest in the memecoin launchpad letsBONK.fun and actively manages its treasury of BONK tokens.
About CRIS Curis Inc.
Curis Inc is a biotechnology company that develops and commercializes drugs and therapies in the immuno-oncology and precision oncology therapeutic areas. The company targets solid tumors, diffuse large B-cell lymphoma, solid tumors or lymphomas, hematological cancers, and others. Its pipeline products include Fimepinostat, CA-170, CA-4948, CA-327, and Erivedge.